Global Irritable Bowel Syndrome (IBS) Market Analysis and Forecast 2024-2030
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
According to APO Research, The global Irritable Bowel Syndrome (IBS) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Includes
This report presents an overview of global market for Irritable Bowel Syndrome (IBS), market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Irritable Bowel Syndrome (IBS), also provides the revenue of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome (IBS), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Irritable Bowel Syndrome (IBS) revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Irritable Bowel Syndrome (IBS) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Irritable Bowel Syndrome (IBS) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc and Astellas Pharmaceuticals, etc.
Irritable Bowel Syndrome (IBS) segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome (IBS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome (IBS) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome (IBS).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Irritable Bowel Syndrome (IBS) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome (IBS) revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
According to APO Research, The global Irritable Bowel Syndrome (IBS) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Includes
This report presents an overview of global market for Irritable Bowel Syndrome (IBS), market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Irritable Bowel Syndrome (IBS), also provides the revenue of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome (IBS), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Irritable Bowel Syndrome (IBS) revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Irritable Bowel Syndrome (IBS) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Irritable Bowel Syndrome (IBS) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc and Astellas Pharmaceuticals, etc.
Irritable Bowel Syndrome (IBS) segment by Company
- Bausch Health
- Allergan
- Takeda
- Sucampo Pharmaceuticals (Mallinckrodt)
- Sebela Pharmaceuticals Inc
- Astellas Pharmaceuticals
- IBS-D Drug
- IBS-C Drug
- Others
- Women
- Men
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome (IBS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome (IBS) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome (IBS).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Irritable Bowel Syndrome (IBS) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome (IBS) revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Irritable Bowel Syndrome (IBS) Market by Type
1.2.1 Global Irritable Bowel Syndrome (IBS) Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 IBS-D Drug
1.2.3 IBS-C Drug
1.2.4 Others
1.3 Irritable Bowel Syndrome (IBS) Market by Application
1.3.1 Global Irritable Bowel Syndrome (IBS) Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Women
1.3.3 Men
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 IRRITABLE BOWEL SYNDROME (IBS) MARKET DYNAMICS
2.1 Irritable Bowel Syndrome (IBS) Industry Trends
2.2 Irritable Bowel Syndrome (IBS) Industry Drivers
2.3 Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges
2.4 Irritable Bowel Syndrome (IBS) Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Irritable Bowel Syndrome (IBS) Market Perspective (2019-2030)
3.2 Global Irritable Bowel Syndrome (IBS) Growth Trends by Region
3.2.1 Global Irritable Bowel Syndrome (IBS) Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Irritable Bowel Syndrome (IBS) Market Size by Region (2019-2024)
3.2.3 Global Irritable Bowel Syndrome (IBS) Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Irritable Bowel Syndrome (IBS) Revenue by Players
4.1.1 Global Irritable Bowel Syndrome (IBS) Revenue by Players (2019-2024)
4.1.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Players (2019-2024)
4.1.3 Global Irritable Bowel Syndrome (IBS) Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Irritable Bowel Syndrome (IBS) Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Irritable Bowel Syndrome (IBS) Key Players Headquarters & Area Served
4.4 Global Irritable Bowel Syndrome (IBS) Players, Product Type & Application
4.5 Global Irritable Bowel Syndrome (IBS) Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Irritable Bowel Syndrome (IBS) Market CR5 and HHI
4.6.2 Global Top 5 and 10 Irritable Bowel Syndrome (IBS) Players Market Share by Revenue in 2023
4.6.3 2023 Irritable Bowel Syndrome (IBS) Tier 1, Tier 2, and Tier
5 IRRITABLE BOWEL SYNDROME (IBS) MARKET SIZE BY TYPE
5.1 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
5.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2019-2030)
6 IRRITABLE BOWEL SYNDROME (IBS) MARKET SIZE BY APPLICATION
6.1 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
6.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Bausch Health
7.1.1 Bausch Health Comapny Information
7.1.2 Bausch Health Business Overview
7.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio
7.1.5 Bausch Health Recent Developments
7.2 Allergan
7.2.1 Allergan Comapny Information
7.2.2 Allergan Business Overview
7.2.3 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio
7.2.5 Allergan Recent Developments
7.3 Takeda
7.3.1 Takeda Comapny Information
7.3.2 Takeda Business Overview
7.3.3 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio
7.3.5 Takeda Recent Developments
7.4 Sucampo Pharmaceuticals (Mallinckrodt)
7.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Comapny Information
7.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Business Overview
7.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio
7.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
7.5 Sebela Pharmaceuticals Inc
7.5.1 Sebela Pharmaceuticals Inc Comapny Information
7.5.2 Sebela Pharmaceuticals Inc Business Overview
7.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio
7.5.5 Sebela Pharmaceuticals Inc Recent Developments
7.6 Astellas Pharmaceuticals
7.6.1 Astellas Pharmaceuticals Comapny Information
7.6.2 Astellas Pharmaceuticals Business Overview
7.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio
7.6.5 Astellas Pharmaceuticals Recent Developments
8 NORTH AMERICA
8.1 North America Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
8.2 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
8.2.1 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
8.2.2 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
8.3 North America Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
8.4 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
8.4.1 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
8.4.2 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
8.5 North America Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
8.6 North America Irritable Bowel Syndrome (IBS) Revenue by Country
8.6.1 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
8.6.3 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
9.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
9.2.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
9.2.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
9.3 Europe Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
9.4 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
9.4.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
9.4.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
9.5 Europe Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
9.6 Europe Irritable Bowel Syndrome (IBS) Revenue by Country
9.6.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
9.6.3 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
10.2 China Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
10.2.1 China Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
10.2.2 China Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
10.3 China Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
10.4 China Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
10.4.1 China Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
10.4.2 China Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
10.5 China Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
11.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
11.2.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
11.2.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
11.3 Asia Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
11.4 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
11.4.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
11.4.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
11.5 Asia Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
11.6 Asia Irritable Bowel Syndrome (IBS) Revenue by Country
11.6.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
11.6.3 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
12.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
12.2.1 MEALA Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
12.2.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
12.3 MEALA Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
12.4 MEALA Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
12.4.1 MEALA Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
12.4.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
12.5 MEALA Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
12.6 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country
12.6.1 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
12.6.3 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Irritable Bowel Syndrome (IBS) Market by Type
1.2.1 Global Irritable Bowel Syndrome (IBS) Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 IBS-D Drug
1.2.3 IBS-C Drug
1.2.4 Others
1.3 Irritable Bowel Syndrome (IBS) Market by Application
1.3.1 Global Irritable Bowel Syndrome (IBS) Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Women
1.3.3 Men
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 IRRITABLE BOWEL SYNDROME (IBS) MARKET DYNAMICS
2.1 Irritable Bowel Syndrome (IBS) Industry Trends
2.2 Irritable Bowel Syndrome (IBS) Industry Drivers
2.3 Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges
2.4 Irritable Bowel Syndrome (IBS) Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Irritable Bowel Syndrome (IBS) Market Perspective (2019-2030)
3.2 Global Irritable Bowel Syndrome (IBS) Growth Trends by Region
3.2.1 Global Irritable Bowel Syndrome (IBS) Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Irritable Bowel Syndrome (IBS) Market Size by Region (2019-2024)
3.2.3 Global Irritable Bowel Syndrome (IBS) Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Irritable Bowel Syndrome (IBS) Revenue by Players
4.1.1 Global Irritable Bowel Syndrome (IBS) Revenue by Players (2019-2024)
4.1.2 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Players (2019-2024)
4.1.3 Global Irritable Bowel Syndrome (IBS) Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Irritable Bowel Syndrome (IBS) Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Irritable Bowel Syndrome (IBS) Key Players Headquarters & Area Served
4.4 Global Irritable Bowel Syndrome (IBS) Players, Product Type & Application
4.5 Global Irritable Bowel Syndrome (IBS) Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Irritable Bowel Syndrome (IBS) Market CR5 and HHI
4.6.2 Global Top 5 and 10 Irritable Bowel Syndrome (IBS) Players Market Share by Revenue in 2023
4.6.3 2023 Irritable Bowel Syndrome (IBS) Tier 1, Tier 2, and Tier
5 IRRITABLE BOWEL SYNDROME (IBS) MARKET SIZE BY TYPE
5.1 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
5.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Type (2019-2030)
6 IRRITABLE BOWEL SYNDROME (IBS) MARKET SIZE BY APPLICATION
6.1 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
6.3 Global Irritable Bowel Syndrome (IBS) Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Bausch Health
7.1.1 Bausch Health Comapny Information
7.1.2 Bausch Health Business Overview
7.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio
7.1.5 Bausch Health Recent Developments
7.2 Allergan
7.2.1 Allergan Comapny Information
7.2.2 Allergan Business Overview
7.2.3 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio
7.2.5 Allergan Recent Developments
7.3 Takeda
7.3.1 Takeda Comapny Information
7.3.2 Takeda Business Overview
7.3.3 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio
7.3.5 Takeda Recent Developments
7.4 Sucampo Pharmaceuticals (Mallinckrodt)
7.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Comapny Information
7.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Business Overview
7.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio
7.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
7.5 Sebela Pharmaceuticals Inc
7.5.1 Sebela Pharmaceuticals Inc Comapny Information
7.5.2 Sebela Pharmaceuticals Inc Business Overview
7.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio
7.5.5 Sebela Pharmaceuticals Inc Recent Developments
7.6 Astellas Pharmaceuticals
7.6.1 Astellas Pharmaceuticals Comapny Information
7.6.2 Astellas Pharmaceuticals Business Overview
7.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
7.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio
7.6.5 Astellas Pharmaceuticals Recent Developments
8 NORTH AMERICA
8.1 North America Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
8.2 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
8.2.1 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
8.2.2 North America Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
8.3 North America Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
8.4 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
8.4.1 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
8.4.2 North America Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
8.5 North America Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
8.6 North America Irritable Bowel Syndrome (IBS) Revenue by Country
8.6.1 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
8.6.3 North America Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
9.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
9.2.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
9.2.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
9.3 Europe Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
9.4 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
9.4.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
9.4.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
9.5 Europe Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
9.6 Europe Irritable Bowel Syndrome (IBS) Revenue by Country
9.6.1 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
9.6.3 Europe Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
10.2 China Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
10.2.1 China Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
10.2.2 China Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
10.3 China Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
10.4 China Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
10.4.1 China Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
10.4.2 China Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
10.5 China Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
11.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
11.2.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
11.2.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
11.3 Asia Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
11.4 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
11.4.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
11.4.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
11.5 Asia Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
11.6 Asia Irritable Bowel Syndrome (IBS) Revenue by Country
11.6.1 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
11.6.3 Asia Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Irritable Bowel Syndrome (IBS) Revenue (2019-2030)
12.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2030)
12.2.1 MEALA Irritable Bowel Syndrome (IBS) Revenue by Type (2019-2024)
12.2.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Type (2025-2030)
12.3 MEALA Irritable Bowel Syndrome (IBS) Revenue Share by Type (2019-2030)
12.4 MEALA Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2030)
12.4.1 MEALA Irritable Bowel Syndrome (IBS) Revenue by Application (2019-2024)
12.4.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Application (2025-2030)
12.5 MEALA Irritable Bowel Syndrome (IBS) Revenue Share by Application (2019-2030)
12.6 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country
12.6.1 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country (2019-2024)
12.6.3 MEALA Irritable Bowel Syndrome (IBS) Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
